-adrenergic blocking and cardiovascular properties of a new compound, 1-(7-indenyloxy)-3-isopropylaminopropan-2-ol-hydrochloride (YB-2).
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists; D000526:Alprenolol / Q000494:pharmacology; D000605:Amino Alcohols / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D007275:Injections, Intravenous; D008297:Male; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D013997:Time Factors; D014599:Uterus / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D000526:Alprenolol; D011433:Propranolol